Rostec’s Nacimbio holding and the Human Stem Cell Institute (HSCI) has signed an agreement on the development of a combination influenza and COVID-19 vaccine. Only one vaccination will be enough to protect against two diseases simultaneously. Clinical study of the vaccine formulation is to be started in the second half of 2022.
The development is based on Nacimbio’s experience in the development of multicomponent vaccines that contain several types of viral antigens rather than one type. The new vaccine will contain components against four influenza strains made by Rostec’s pharmaceutical holding and HSCI’s proprietary vaccine platform. Currently, Nacimbio produces Ultrix Quadri tetravalent vaccine and a range of combination vaccines, including the measles, mumps and rubella vaccine, DTP group vaccines and many others.
“The effect of combining technology expertise provided by the two leading biopharmaceutical market players – our Nacimbio holding and the Human Stem Cell Institute – will enable to launch onto the market the high-demand new product that is necessary for health protection in Russia. Among many technologies that have been reviewed, we have chosen the HSCI’s platform as the most suitable and technology-relevant one for the joint project. We are planning to complete the pre-clinical study of the vaccine in the 3rd quarter of 2022,” said Sergey Chemezov, CEO of Rosteс State Corporation.
The combination influenza and COVID-19 vaccine will be developed on the HSCI’s technology platform with mass production to be launched at one of Nacimbio’s pharmaceutical plants.
